Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

St. Jude Medical to display new products, clinical solutions at Heart Rhythm 2010

St. Jude Medical, Inc., a global medical device company, today announced it will display a number of new products and clinical solutions from the company's Cardiac Rhythm Management and Atrial Fibrillation Divisions at Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

13 May 2010

FDA approves St. Jude Medical's Unify CRT-D and Fortify ICD devices

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval and first U.S. implants of its Unify™ cardiac resynchronization therapy defibrillator (CRT-D) and Fortify™ implantable cardioverter defibrillator (ICD). The new devices feature advanced battery technology and circuitry that allow for the smallest device footprint in the industry and rapid charge times, without any compromise in device longevity or power.

13 May 2010

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.

13 May 2010

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Clinical Data, Inc., announced today that its PGxHealth division is expanding its FAMILION family of genetic tests to include two new tests to diagnose heart diseases. With the launch of a test for Conduction Disease associated with Dilated Cardiomyopathy and a test for Short QT Syndrome, PGxHealth continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases.

12 May 2010

St. Jude Medical launches Promote Quadra CRT-D in Europe

St. Jude Medical, Inc., a global medical device company, today announced the European launch of its Promote Quadra™ cardiac resynchronization therapy defibrillator (CRT-D). The Promote Quadra CRT-D is the industry's first quadripolar pacing system, which offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

12 May 2010

CHD mortality rate in Ontario decreased by 35%: Study

From 1994 to 2005 in Ontario, Canada, there was a 35 percent decrease in the rate of deaths from coronary heart disease, with about half of this reduction associated with improvements in traditional CHD risk factors such as total cholesterol levels and systolic blood pressure, according to a study in the May 12 issue of JAMA.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to the Company's LATITUDE® Patient Management system. The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices. The upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data.

12 May 2010

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

The scientific evidence linking air pollution to heart attacks, strokes and cardiovascular death has "substantially strengthened," and people, particularly those at high cardiovascular risk, should limit their exposure, according to an updated American Heart Association scientific statement.

11 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Researchers study link between cognitive impairment and adherence problems among HF patients

Surviving heart failure calls for lifestyle changes, taking medications and following doctor's orders. Some of the 5 million heart failure patients have trouble adhering to these changes and end up returning to the hospital.

10 May 2010

Kent State University receives four-year, $2.7M grant to study cognitive status of heart failure patients

The National Institutes of Health has awarded a $2.7-million grant to Kent State University for a collaborative research project with Case Western Reserve University School of Nursing, Summa Health System in Akron and University Hospitals Case Medical Center in Cleveland to study cognitive impairment in heart failure patients.

7 May 2010

CardioMEMS completes $37.9M financing

CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.

7 May 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump.

7 May 2010

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.

7 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Study: Hospital follow up can curb readmission rate for heart patients

"Hospitals can slow the revolving door that shuttles heart failure patients back into bed within a month of going home by following up promptly to ensure patients get the right outpatient care, a study shows," USA Today reports.

6 May 2010

Study finds early follow-up for heart failure patients reduces readmission rates

Hospitals that have a higher rate of following up within one week for patients who were discharged after treatment for heart failure have a lower rate of readmission at 30 days for these patients, according to a study in the May 5 issue of JAMA.

5 May 2010

Heart Failure News and Research

Further Reading

St. Jude Medical to display new products, clinical solutions at Heart Rhythm 2010

FDA approves St. Jude Medical's Unify CRT-D and Fortify ICD devices

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

St. Jude Medical launches Promote Quadra CRT-D in Europe

CHD mortality rate in Ontario decreased by 35%: Study

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Researchers study link between cognitive impairment and adherence problems among HF patients

Kent State University receives four-year, $2.7M grant to study cognitive status of heart failure patients

CardioMEMS completes $37.9M financing

Cytori Therapeutics to initiate European medical device approval study for Celution System

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

RayBiotech announces biomarker grant winners

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Study: Hospital follow up can curb readmission rate for heart patients

Study finds early follow-up for heart failure patients reduces readmission rates

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News